We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The vaccine was approved after it was found to meet the MHRA’s standards of safety, quality and effectiveness.
Moderna to invest in mRNA research and development (R&D) in the UK, and build a state-of-the-art vaccine manufacturing centre with the ability to produce up to 250 million vaccines a year.
This adapted COVID-19 vaccine targets both the original coronavirus (SARS-CoV-2) and the Omicron BA.4 and BA.5 sub-variants.
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
Biotech company Moderna has published positive efficacy results from its Phase 3 studies of its potential COVID-19 vaccine.
The move aims to help accelerate the booster programme and get jabs in arms more quickly in light of rising cases of Omicron.
The adapted COVID-19 vaccine made by Moderna targets two different coronavirus variants: the original virus from 2020 and the Omicron variant
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.